Company News

Share this article:

Maryland-based Osiris Therapeutics announced the creation of a new biosurgery division focused on developing and marketing high-end biological products used in surgical procedures. The company hopes to build on the success of Osteocel, an implantable product launched in 2005. Osteocel generated over $40 million in revenue before being sold in 2008 to Nuvasive for “up to $85 million,” according to a company release.

California-based Eiger BioPharmaceuticals acquired an exclusive license from Stanford University for its hepatitis C virus technology. The technology was discovered in the lab of Stanford scientist and Eiger founder Jeffrey Glenn. Financial terms of the deal were not disclosed.


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.